ENDPOINTS

ArriVent plots next steps for lung cancer drug; Neuron23's $96.5M raise

Plus, news about Rivus, Amarin, Recordati, Liquidia, Healthcare Royalty, Lexeo, Perceptive, venBio, Novo Nordisk and Cidara: ArriVent to start another Phase 3 of lung cancer drug: In a Phase 1b trial, the Pennsylvania biotech is ...

Jun 24, 2025 - 16:10
 0
ArriVent plots next steps for lung cancer drug; Neuron23's $96.5M raise
Plus, news about Rivus, Amarin, Recordati, Liquidia, Healthcare Royalty, Lexeo, Perceptive, venBio, Novo Nordisk and Cidara: ArriVent to start another Phase 3 of lung cancer drug: In a Phase 1b trial, the Pennsylvania biotech is ...
Read More

Tags:

Previous Article

Northern lights may be visible in these 14 US States on June 25

Next Article

From Data Silos to Integrated Care: Driving Provider Engagement

Related Posts

Scholar Rock reports competitive data for muscle-preserving obesity drug add-on

Scholar Rock reports competitive data for muscle-preser...

Jun 18, 2025  0

NextCure inks ADC deal with Simcere Zaiming

NextCure inks ADC deal with Simcere Zaiming

Jun 16, 2025  0

Updated: MD Anderson-allied investment firm targets $250M for second cancer biotech fund

Updated: MD Anderson-allied investment firm targets $25...

May 28, 2025  0